Targeting BCL2 for the Treatment of Lymphoid Malignancies  by Anderson, Mary Ann et al.
Targeting BCL2 for the Treatment of Lymphoid
Malignancies
Mary Ann Anderson,a,b,c David Huang,c,d and Andrew Robertsa,b,c,dThe failure of apoptosis (programmed cell death) underpins the development of many tumors and often0037-1963
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Seminarsrenders them resistant to cytotoxic therapies. In hematologic malignancies, this impairment of apoptosis is
often caused by overexpression of the pro-survival protein BCL2. Because abnormally high levels of BCL2
sustain these tumors, there has been much interest in targeting BCL2 as a novel approach to treating
various hematologic malignancies. One such approach is the development of BH3 mimetic compounds,
small molecules that mimic the action of the BH3-only proteins, natural antagonists of BCL2 and its pro-
survival relatives. These compounds act by restoring the ability of a cell to undergo apoptotic cell death.
Some of them have shown very encouraging results in early-phase clinical trials that are currently
underway, particularly in patients with chronic lymphocytic leukemia and some non-Hodgkin
lymphomas, diseases marked by BCL2 overexpression. In this review, we discuss the rationale behind
targeting BCL2, highlight the recent ﬁndings from clinical trials, and pinpoint the next steps in the
clinical development of this interesting and promising class of targeted agents, particularly for the
treatment of lymphoid malignancies.
Semin Hematol 51:219–227. C 2014 Elsevier Inc. Open access under CC BY-NC-ND license.The last 50 years have seen remarkable advancesin the medical management of many varieties ofhematologic malignancy. Among these are treat-
ments for chronic myeloid leukemia (CML) and acute
promyelocytic leukemia (APML), diseases in whichevier Inc.
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Open access under CC BY-NC-ND license.molecularly targeted agents developed to speciﬁcally
correct the key aberrant features of those diseases (dysre-
gulated ABL kinase activity in CML or differentiation
arrest in APML) have radically altered both the manage-
ment and the prognosis in these diseases. In both
instances, therapy has been well tolerated with minimal
adverse effects because normal tissues are relatively
spared.
These successes serve as paradigms for developing other
targeted anticancer therapies, the goal being to selectively
target the key molecular drivers that sustain a speciﬁc
tumor. Optimally, this therapy should maximize the
antitumor effect with minimal toxicities due to on- or
off-target activities. However, this goal has proven to be
very challenging for most hematologic malignancies
because the underlying genetic drivers are usually hetero-
geneous and complex. This outcome is in contrast with
CML or APML, diseases driven and sustained largely by
single molecular abnormalities.
Ever since resistance to apoptosis was identiﬁed as a
hallmark of many cancers,1,2 it has been recognized that
therapies aimed at restoring the ability of malignant cells
to undergo apoptosis might result in their killing with
relative sparing of normal tissues. In the present review, we
explore the background to newer therapies designed to
overcome the blocks in apoptosis, focusing on small-
molecule inhibitors of BCL2 that are now in clinical
development, especially for treating patients with lym-
phoid malignancies.219
Figure 1. Control of apoptosis by the BCL2 protein
family.4 (A) In normal, untransformed mature B lympho-
cytes, BCL2 maintains cellular viability by blocking apop-
tosis. (B) When a signiﬁcant stress signal is applied
(eg, DNA or microtubular damage, cytokine deprivation,
oxidative stress), the BH3-only proteins are activated. By
binding to and inactivating BCL2 and related pro-survival
proteins, these BH3-only proteins allow apoptosis to
proceed. Some BH3-only proteins can directly activate
BAX and/or BAK.
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PROTEIN FAMILY
Apoptosis is a stereotypical process of cell death
intrinsic to all multicellular eukaryotic organisms and is
critical for the elimination of unwanted, infected, or
otherwise damaged cells.3 The effectors of this process
are caspases, proteolytic enzymes that drive cellular dem-
olition from within. Apoptosis is initiated by two major
signaling pathways: (1) the extrinsic or death receptor
pathway; and (2) the intrinsic or mitochondrial pathway.
The former is activated when extracellular death ligands of
the tumor necrosis factor family (eg, Fas/CD95) bind to
speciﬁc cell surface receptors to trigger intra-cellular
signals, culminating in the activation of caspases.
However, it is the intrinsic pathway that is more
commonly perturbed in lymphoid malignancies. Cell death
mediated through this pathway is regulated by members of
a family of proteins related to BCL2. This family is
considered to contain three subfamilies: pro-survival
(BCL2 and the closely related proteins BCLxL, BCLw,
MCL1, and BFL1/A1); and subfamilies that promote cell
death, the initiator BH3-only proteins (BIM, PUMA,
BAD, or NOXA), and the cell death mediators, BAX
and BAK. The interactions between these intra-cellular
proteins determine whether a cell lives or dies.4,5
Under normal conditions in healthy lymphoid cells, the
pro-survival members of the BCL2 family constrain the
essential cell death mediators, BAX and BAK, thus
maintaining cellular viability (Figure 1A). Stress signals
such as DNA damage (eg, those induced by chemotherapy
or radiation) or lack of growth factors trigger the activation
of the BH3-only proteins such as BIM (Figure 1B). These
BH3-only proteins bind to and inactivate the pro-survival
family members, such as BCL2, to allow activation of
BAX and BAK. Some BH3-only proteins can also directly
activate BAX and BAK. In any individual cell, the relative
activity of the BH3-only proteins and pro-survival BCL2
proteins determine the level of BAX and BAK activation
and thus whether it lives or dies by apoptosis. Once
activated, BAX and BAK permeabilize the outer mito-
chondrial membrane, triggering the release of factors such
as cytochrome c, which functions as a co-factor for the
activation of caspases, as well as damaging the mitochon-
dria, the cell’s major energy source.6IMPAIRMENT OF APOPTOSIS IN LYMPHOID
MALIGNANCIES
Signaling for apoptosis through the intrinsic pathway
could fail by reduction in the activity of the BH3-only
proteins, overactivity of the pro-survival BCL2 proteins, or
loss of BAX and/or BAK (Figure 2). In lymphoid
malignancies, the most common mutations are those
affecting the tumor suppressor TP53, which normally acts
to activate certain BH3-only proteins (eg, PUMA,
NOXA) and the overexpression of BCL2. The latter ischaracteristic of follicular lymphoma7,8 and is uniformly
present in chronic lymphocytic leukemia (CLL),9 whereby
the impairment of apoptosis caused by BCL2 overactivity
results in the accumulation of mature CD5þCD19þ
lymphocytes in the blood and other lymphoid organs.
Overexpression of BCL2 is also a feature of multiple
myeloma and other plasma cell dyscrasias,10 mantle cell
lymphoma (MCL),11 diffuse large B-cell lymphoma,12
acute lymphoblastic leukemia,13 and some T-cell
lymphomas.14
Cells in which there is an excess of BCL2 are
inappropriately long-lived despite endogenous or exoge-
nous death stimuli. Moreover, because many cytotoxic
therapies trigger apoptosis by activating the BH3-only
proteins, the elevated levels of BCL2 found in many
lymphoid malignancies can contribute to therapy resist-
ance by blocking apoptosis.15 Paradoxically, BCL2-
overexpressing cells have been described as “primed for
death”16,17; that is, if minor changes in the ratio of activity
of pro-survival BCL2 family proteins to the activity of
BH3-only proteins can be achieved, then apoptosis will be
induced.EARLY ATTEMPTS TO TARGET BCL2
These considerations led to BCL2 being identiﬁed as
an attractive therapeutic target for 42 decades, especially
Figure 2. In malignant lymphoid cells, stress-induced apoptosis may be impaired through a number of different
mechanisms, including: (A) overactivity of the pro-survival BCL2 proteins; (B) reduced BH3-only protein expression or
activation; and (C) loss of BAX and/or BAK. BCL2 overexpression prevents apoptosis when the cell is stressed, despite
activation of BH3-only proteins to a level that would be sufﬁcient to induce apoptosis in a normal lymphocyte. BCL2-
overexpressing cells are therefore protected from apoptosis and accumulate inappropriately in vivo.
BCL2 for the treatment of lymphoid malignancies 221for lymphoid malignancies. Earlier attempts focused on
interfering with BCL2 gene expression, thereby reducing
the level of BCL2 protein synthesized. Oblimersen (Gen-
asense, Genta, NJ), an antisense oligonucleotide that binds
to BCL2 mRNA, thus interfering with its translation, was
considered to have signiﬁcant potential during early
development18 but ultimately proved in Phase III studies
to have insufﬁcient clinical efﬁcacy.19 Although the drug
could induce apoptosis in vitro, it also induced tumor cell
death by other pathways18 (eg, induction of antiviral res-
ponses). It also seems likely that the failure of oblimersen
reﬂects a failure to sufﬁciently reduce BCL2 levels, and
hence BCL2 activity, within malignant cells. An alter-
native approach to directly inhibit the function of BCL2
has been pursued, with some success.Figure 3. Selectivity of the BH3-only proteins for the
pro-survival BCL2 proteins. Some BH3-only proteins (eg,
BIM) bind all the pro-survival BCL2 proteins, whereas
others (eg, BAD, NOXA) have preferential binding part-
ners.20 Within a cell, the reservoir of pro-survival BCL2
proteins determines whether a cell lives or dies, and this
action is in turn controlled by whether they are inacti-
vated by the BH3-only proteins. Hence, the amounts and
binding selectivities of the BH3-only proteins determine
whether apoptosis proceeds. Adapted from Chen et al.20BH3 MIMETIC AGENTS TO INHIBIT BCL2 AND
ITS RELATIVES
As discussed earlier, BCL2 and its closest relatives
constrain BAX and BAK, thereby keeping cells alive
(Figure 1). They do so directly by binding to the cell
death mediators or indirectly by sequestering BH3-only
proteins such as BIM, which can activate BAX and BAK.4
Importantly, the BH3-only proteins antagonize pro-
survival BCL2 and its relatives by binding with high
afﬁnity to a groove on their surfaces. When a cell is
stressed, the elevated levels of the BH3-only proteins
titrate out the amount of the pro-survival BCL2 proteins
available to keep BAX and BAK in check, thereby allowing
apoptosis to ensue.
Although some BH3-only proteins (eg, BIM) bind to all
the pro-survival proteins, others are much more selective.
BAD, for example, has high afﬁnity for BCL2, BCLxL, and
BCLw, whereas NOXA binds preferentially to MCL120(Figure 3). Conceptually, these ﬁndings suggest that
selective targeting of BCL2 and its relatives is feasible and
explains in part the biological consequences of activating
one BH3-only protein (eg, BAD) compared with activating
another (eg, NOXA).
The detailed molecular and structural understanding of
how the BH3-only proteins act to initiate apoptosis was
crucial to attempts to functionally target BCL2 and its
relatives. Although it is relatively straightforward to
develop inhibitors for enzymes such as kinases (eg, ABL,
B-RAF), targeting the protein–protein interaction (eg, that
between BCL2 protein family members) has long been
considered to be highly challenging—the “holy grail” of
drug discovery. However, the deployment of novel drug
discovery methods, including technical innovations such
Figure 4. BH3 mimetic compounds re-sensitize BCL2-
overexpressing tumor cells to apoptosis. The BH3
mimetic compounds are drugs that mimic the function
of endogenous BH3-only proteins. At relevant pharma-
cologic concentrations, the BH3 mimetic agents bind
and inhibit excess BCL2 (and related pro-survival pro-
teins), thereby unleashing apoptosis.23
M.A. Anderson et al222as SAR-by-NMR (structure–activity relationships obtained
from nuclear magnetic resonance),21,22 detailed under-
standing obtained from molecular and structural studies
combined with state-of-the-art medicinal chemistry have
enabled the discovery and development of small-molecule
inhibitors of BCL2 and its relatives: the BH3 mimetic
compounds.23
Given the early experience with oblimersen and partic-
ularly because many chemicals can induce cell killing, it is
critical to clearly distinguish the BH3 mimetic agents from
other drugs. In this regard, four criteria have been proposed
to assess how closely these agents act like the BH3-only
proteins, the natural antagonists23 (Figure 4): (1) the
biological activity of the agent must be to induce apoptosis
via mitochondrial disruption by BAX and BAK; (2) the
agent must bind to at least one BCL2 family member with
high afﬁnity; (3) the activity of the agent must correlate
with the expression of the relevant BCL2 family members
in the cell of interest; and (4) relevant biomarkers should
be affected by the agent in animal models.
A detailed consideration of four putative BH3 mimetic
inhibitors of BCL2 that have entered clinical trials illustrate
the relevance of these criteria for clinical development.CLINICAL EXPERIENCE WITH PUTATIVE BH3
MIMETICS
Obatoclax (GX15-070) has been described as a pan–
BCL2 family inhibitor. It binds to BCL2, BCLxL, BCLw,
and MCL1 with low micromolar afﬁnity and reportedlykills cells via BAX and BAK.24 However, the response rates
in clinical trials have been low,25,26 and its development
has ceased.
The natural product gossypol and its synthetic deriva-
tive AT-101 binds BCL2, BCLxL, and MCL1.
27–29
However, the cell killing induced is not entirely mediated
by BAX and BAK, indicating that the drug kills through
multiple mechanisms.30 As with obatoclax, these agents
have demonstrated minimal single-agent activity in clinical
trials, although some efﬁcacy was observed in patients with
follicular lymphoma when combined with rituximab.31–33
ABT-737 is an extensively validated BH3 mimetic,
discovered by using SAR-by-NMR and redeﬁned through
structure-guided medicinal chemistry efforts.22 Its descrip-
tion in 2005 dramatically advanced the ﬁeld. ABT-737
binds to and inhibits BCL2, BCLxL, and BCLw with high
afﬁnity (Ki o1 nM for all) but has  500-fold weaker
binding to MCL1 and BFL1/A1 (lower Ki values reﬂect
tighter binding to the target). Although the binding assays
undertaken in different laboratories cannot always be
directly compared, this binding afﬁnity probably repre-
sents much greater afﬁnity for BCL2, BCLxL, and BCLw
than that reported for the BH3 mimetic agents described
earlier. The in vitro killing by ABT-737 is entirely
dependent on the presence of BAX/BAK.30 Its in vitro
killing activity also correlates to the expression of the
relevant BCL2 family proteins such that reduction of
MCL1, which is not targeted by ABT-737, sensitizes cell
lines to death in response to the agent, and cell lines
overexpressing BCL2 remain sensitive to death.30,34 Fur-
thermore, in mouse lymphoma models, its activity corre-
lates with expression of relevant BCL2 family members.35
ABT-737 and its orally available analogue ABT-263 demon-
strate signiﬁcant preclinical efﬁcacy in a range of hemato-
poietic malignancies.36–38
ABT-737 was not suitable for clinical development as
an oral agent. However, its orally bioavailable relative,
ABT-263, also binds to and inhibits BCL2, BCLxL, and
BCLw (Ki o1 nM for all)38 and entered clinical trials in
2006. ABT-263, also known as navitoclax, has provided
the ﬁrst insights into the potential beneﬁts and pitfalls of
this class of agent for the treatment of patients with
lymphoid malignancies.
Navitoclax induced a 35% overall response rate (ORR)
in patients with relapsed and refractory CLL in a Phase I/II
trial.39 The best outcome achieved in this study was partial
remission (PR) when CLL burden was assessed in the
blood, lymph nodes, and bone marrow. Responses were
durable in many patients, and a progression-free survival
(PFS) of 25 months was reported. Notably, responses were
seen in patients with poor prognostic features, including
del17p, bulky disease, and ﬂudarabine-refractory cases.
Final analyses of Phase II data in relapsed refractory CLL
and in ﬁrst-line CLL treatment are awaited.
In a Phase I trial of navitoclax involving patients with a
variety of non-Hodgkin lymphomas (NHLs), an ORR of
22% was observed, composed entirely of PRs, and a PFS
Figure 5. Selectivity of some BH3 mimetic compounds.
Like the BH3-only protein BAD (as seen in Figure 3),
navitoclax (ABT-263) binds tightly to BCL2, BCLxL, and
BCLw but spares MCL1 and BFL1/A1.38 However, dosing
of navitoclax (ABT-263) is limited by thrombocytopenia
triggered by the targeting of BCLxL.39,41,42 By engineer-
ing navitoclax (ABT-263), the selective BCL2 inhibitor
ABT-199 was developed.45 Because thrombocytopenia
is not dose-limiting for ABT-199, it should allow the
clinical impact of selectively inhibiting BCL2 to be fully
evaluated.
BCL2 for the treatment of lymphoid malignancies 223of 16 months was estimated.40 These clinical results
represent a signiﬁcant advance on clinical activity observed
with obatoclax and AT-101. Given the apparently much
weaker binding afﬁnities of these two drugs compared
with navitoclax, this ﬁnding suggests that BH3 mimetic
agents require tight binding afﬁnities in the low nano-
molar range (or better) to have meaningful clinical
activity.
Dose escalation in the Phase I CLL clinical trials of
navitoclax (ABT-263) was limited by acute, dose-
dependent thrombocytopenia,39 and all patients experi-
enced a predictable decrease in their platelet counts from
baseline within several days on the recommended Phase II
dose. This adverse effect on platelets is the result of “on-
target” BCLxL inhibition. In mice, BCLxL is critical to
maintaining the viability of peripheral circulating plate-
lets,15,41,42 and genetic experiments have excluded BCL2
as playing any role in maintaining the viability of
circulating platelets.15 This dose-limiting toxicity of
thrombocytopenia meant that the maximum tolerated
exposure to navitoclax (ABT-263) was capped, compro-
mising assessment of efﬁcacy rates at higher doses. Grade
3 and 4 neutropenia was also noted in up to 29% of
patients40 in the navitoclax (ABT-263) trials. Neutrophils
do not undergo apoptosis in vitro when treated with ABT-
737 or navitoclax (ABT-263),43 and the mechanism for
this toxicity is still under investigation. Lymphopenia was
a common ﬁnding in the NHL cohort, affecting up to
14% of patients.40 In mouse models, ABT-737 causes a
predictable depletion of B and T lymphocyte subsets.44
Preclinical data had suggested that signiﬁcant MCL1
expression would most likely prevent responses to navito-
clax.30 However, in the Phase I CLL study, MCL1
expression did not preclude clinical responses, although
higher MCL1 expression was associated with lesser reduc-
tion of CLL.39 Mechanistic data now indicate that in B
lymphocytes, direct inhibition of BCL2 by navitoclax (and
ABT-737) displaces BIM from BCL2, making it available
to inhibit MCL1.17,44 Thus, MCL1 expression per se is
not a marker of resistance to navitoclax.SELECTIVE INHIBITION OF BCL2 WITH THE
BH3 MIMETIC ABT-199
The need to develop a BCL2-speciﬁc BH3 mimetic was
apparent from the navitoclax (ABT-263) experience. It
was anticipated that such a drug would be platelet sparing
and not limited by thrombocytopenia, thus allowing com-
plete deﬁnition of BCL2 as a therapeutic target. ABT-199
(GDC-0199/RG7601), generated by re-engineering navi-
toclax (ABT-263), is the ﬁrst such drug described.45 It has
high binding afﬁnity for BCL2 (Ki o1 nM) without
signiﬁcant binding to BCLxL (Ki, 50 nM) or BCLw
(Ki4200 nM) (Figure 5, Table 1). In preclinical studies,
this drug has demonstrated signiﬁcant activity against CLL
peripheral blood samples but not platelets, in vitro, and no
platelet toxicity in mice or dogs treated with ABT-199.45Phase I clinical trials of ABT-199 as a single agent are
currently underway in patients with CLL, NHL, and
multiple myeloma.
ABT-199 has demonstrated the most promising clinical
results of all the putative agents targeting BCL2 to date.
Preliminary results from these Phase I studies demonstrate
an 84% ORR in patients with relapsed or refractory CLL,
including those with bulky disease, ﬂudarabine-refractory
disease, and del17p. In contrast to navitoclax, 23% of
patients have achieved either a complete response (CR) or
a CR with incomplete hematologic recovery.46 These
results hold for patients with ultra-high risk features
(ﬂudarabine refractoriness and del17p) with equivalent
response rates (ORR, 82% and 89%, respectively)
reported in abstract form. As yet, data for PFS have not
reached maturity or been reported. The trial is ongoing,
with accrual to safety expansion cohort at the recom-
mended phase II dose of 400 mg to conclude in mid
2014.
The Phase I ABT-199 trial also includes an arm for
patients with NHL. Preliminary data from this heteroge-
neous group of patients indicate an ORR of 53%
comprising 44% PR and 8% CR.47 An early signal of
particular efﬁcacy has been suggested for mantle cell
lymphoma and Waldenström’s macroglobulinemia, with
ORRs of 82% and 100%, respectively, albeit in a small
number of patients. Results for other subtypes of NHL
have been less impressive, with ORRs of 27% and 38% in
the follicular lymphoma and diffuse large B-cell lymphoma
subgroups. Dose escalation is ongoing for patients
with NHL.47
The higher CLL response rate seen with ABT-199
compared with navitoclax (ABT-263) (ORR, 84% vs
35%) most likely represents higher levels of inhibition of
BCL2. ABT-199 has approximately two-fold higher spe-
ciﬁc bioactivity in vitro against CLL and has been
Table 1. Target Binding Proﬁles of BH3 Mimetic Compounds, and the Clinical Outcomes of Inhibiting Bcl-2 and Its Relatives With These
Compounds
Obatoclax AT-101
Navitoclax
(ABT-263) ABT-199
Target binding (Ki)
*
BCL2 4500 nM 4200 nM o1 nM o1 nM
BCLxL 4500 nM 41000 nM o1 nM 50 nM
MCL-1 4500 nM23 4200 nM33 4500 nM38 4400 nM45
Clinical efﬁcacy
CLL Overall response
rate
4%24 0%31 35%39 84%46
PR 4% 0% 35% 61%
CR/CRi 0% 0% 0% 23%
Median PFS NR NR 25 months NR
NHL Overall response
rate
3%25 NA 22%40 53%47
PR 3% 22% 44%
CR 0% 0% 8%
Median PFS NR 16 months NR
Hematopoietic toxicity
(grades 3/4)
CLL Neutropenia 25%24 0%31 28%39 36%46
Thrombocytopenia 3% (grade 4) 0% 18% (all grade 4) 9%
NHL Neutropenia NA 0%32 18%40 13%47
Thrombocytopenia 0% 29% 11%
Lymphopenia NA 14% NA
Dose-limiting toxicity Neurologic disturbances (ataxia,
somnolence, euphoria) and
infusion-related reactions24
Abnormal liver function
tests31
Thrombocytopenia39 Tumor lysis
syndrome48
Abbreviations: CLL, chronic lymphocytic leukemia; CR, complete response; CRi, CR with incomplete hematologic recovery; NA, not available; NHL, non-Hodgkin lymphoma; NR, not
reported; PFS, progression-free survival; PR, partial remission.
*The smaller value of Ki represents tighter binding to the target and hence more potent activity. Note that the values cited are indicative only.
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Although grade 3 or 4 thrombocytopenia was reported in
9% of ABT-199–treated patients in the CLL arm of the
Phase I trial, the majority of these subjects had pre-existing
CLL-related immune thrombocytopenia, and no correla-
tion between changes in platelet count and dose has been
observed.48 As for navitoclax, grade 3 and 4 neutropenia
has been observed in heavily pretreated patients and
is responsive to treatment with granulocyte colony-
stimulating factor. Episodes of febrile neutropenia are rare,
affecting just 5% of patients with CLL.46 Mature data are
required to determine if ABT-199 treatment is associated
with a higher or lesser risk of infections than seen in other
patients with advanced CLL.
The most signiﬁcant dose-limiting toxicity for ABT-199
has been tumor lysis syndrome (TLS). In vitro, ABT-199
induces apoptosis of CLL very rapidly within 8 hours
(unpublished data, Mary Ann Anderson, 2014). Remark-
ably, TLS has been observed in the same time frame in
several patients at doses ranging between 50 and 1200
mg.48 To date, between the Phase I study and a Phase Ib
trial in combination with rituximab, the rate of signiﬁcant
TLS in CLL patients is 5%, including two deaths and one
acute renal failure. However, the risk seems to be amelio-
rated by the implementation of protocols for the prophy-
laxis of TLS, especially in patients judged to be high risk by
using objective criteria.46TARGETING BCL2 AS PART OF COMBINATION
THERAPY
Although some patients with CLL are achieving CRs
with ABT-199 monotherapy, the potential impact of BH3
mimetic therapy has always been considered to be greater
when used in combination with other anticancer agents.
Although an intrinsic part of their biology, BCL2 over-
expression is not considered the “driver” lesion in lym-
phoid cancers, and it thus seems improbable that even
sustained inhibition of BCL2 will be curative. As discussed
earlier, BCL2 overexpressing cells are “primed for death”
and are variably susceptible to various stressors.16,17 As
with ABT-737 and navitoclax (ABT-263), ABT-199
exhibits potent synergy with various anti-cancer drugs in
preclinical models of mantle cell lymphoma, myeloma,
and diffuse large B-cell lymphoma.45
Clinical trials have begun combination treatment with
anti-CD20 monoclonal antibodies and chemoimmuno-
therapy in patients with CLL (ClinicalTrials.gov identi-
ﬁers NCT01682616, NCT01671904, NCT01889186,
NCT01685892, and NCT02005471) and lymphoma
(NCT01594229) or with bortezomib in patients with
myeloma (NCT01794507). Combinatorial platelet toxic-
ity is not predicted to be problematic as it was in trials
adding navitoclax (ABT-263) to chemotherapy in patients
with solid tumors.49,50 However, neutropenia may be
limiting when ABT-199 is combined with cytotoxic agents
in previously treated patients, and variations in schedulingand dose may be required to ﬁnd the most favorable
balance of efﬁcacy and toxicity.PERSPECTIVES AND FUTURE DIRECTIONS
The clinical trial data with navitoclax (ABT-263) and,
in particular, ABT-199, unequivocally validate BCL2 as a
target for therapy in B-cell lymphoproliferative disorders.
The exploration of the potential for BH3 mimetic com-
pounds as inhibitors of BCL2 is an active area of clinical
and laboratory research, and many key questions are yet to
be resolved. For example, other than high-level BCL2
expression, are there biomarkers which distinguish lym-
phoid malignancies that will respond to ABT-199 as
monotherapy? What is the long-term clinical signiﬁcance
of the CRs being observed in almost one quarter of
patients with relapsed or refractory CLL? What are the
consequences of BCL2 inhibition, and is therapy required
to maintain PFS in patients with CLL? What are the
molecular mechanisms causing primary and/or secondary
treatment failures with ABT-199? In combination settings,
the highest priority question must be to determine if
ABT-199 can synergize with cytotoxic agents to overcome
chemoresistance in currently incurable cancers (eg, “dou-
ble-hit” lymphomas).
Hemato-oncologists now have a suite of powerful new
agents that have the potential to change our current
paradigms for treating several lymphoid malignancies. As
with the introduction of previous novel therapeutic
approaches (eg, combination cytotoxic chemotherapy,
rituximab, and [more recently] tyrosine kinase inhibitors
of B-cell–signaling pathways), time will be required to
answer all the critical questions about how best to deploy
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